# Comprehensive Research Plan: Neurological Diseases & Dengue Cross-Validation

**Doc-Type:** Research Plan · Version 1.0 · Created 2026-01-03 · AI Whisperers

---

## Executive Summary

**Core Conjecture:** Neurology and the nervous system play a significant role in codon expression, which drives PTM accumulation patterns. By exploiting disease-specific data across neurological (ALS, Parkinson's) and immune (Dengue DHF) contexts, we can identify sensitive proteins and validate cross-disease mechanisms using the p-adic codon embedding framework.

**Strategic Goal:** Extend Alejandra Rojas arbovirus surveillance package with neurological disease integration, leveraging existing PTM analysis infrastructure (RA, Tau) and immune escape frameworks (HIV) for comprehensive cross-disease validation.

---

## 1. Core Hypothesis & Validation Strategy

### 1.1 Central Hypothesis Pathway

```
Neurological Context (Motor/Dopaminergic Neurons)
         ↓
Tissue-Specific Codon Usage Bias
         ↓
Differential Translation Efficiency
         ↓
PTM Accumulation Patterns
         ↓
Protein Misfolding / Immune Recognition
         ↓
Disease Phenotype (ALS, Parkinson's, Dengue DHF)
```

### 1.2 Testable Predictions

| Prediction | Validation Method | Existing Tool | Expected Outcome |
|------------|-------------------|---------------|------------------|
| **P1:** Motor neurons show distinct codon bias vs other tissues | RNA-seq codon frequency analysis | TrainableCodonEncoder | High-expressing ALS genes use optimal codons (v=0) |
| **P2:** ALS-associated proteins accumulate specific PTMs | Phosphoproteomics comparison | `ptm_mapping.py` | TDP-43/SOD1 show neuron-specific PTM clusters |
| **P3:** Dengue DHF severity correlates with NS1 PTM patterns | Serotype PTM sweep + HLA binding | RA HLA scripts + PTM database | ADE-prone serotypes have immune-escaping PTM signatures |
| **P4:** Parkinson's dopaminergic neurons show codon-PTM coupling | Alpha-synuclein codon variants vs S129 phosphorylation | `01_tau_phospho_sweep.py` adapted | Codon usage affects aggregation propensity |
| **P5:** Cross-disease PTM patterns cluster in p-adic space | Unified PTM embedding analysis | `padic_dynamics_predictor.py` | Immune-mediated diseases share PTM-induced structural changes |

### 1.3 Cross-Validation Framework

**Three-Way Validation Strategy:**

1. **Neurological → Immune (ALS/PD → Dengue)**
   - If neurological PTMs trigger immune responses (microglia in ALS, dengue immune cells), shared PTM-HLA binding motifs should exist
   - Tool: HIV HLA-peptide analysis → Neuroinflammation epitopes
   - Validation: Do ALS TDP-43 epitopes and Dengue NS1 epitopes show similar p-adic distances?

2. **Immune → Neurological (Dengue → ALS/PD)**
   - Immune cell "handshake" failure in Dengue DHF may parallel protein-protein interaction failures in neurodegeneration
   - Tool: Contact prediction (protein-protein) + immune escape (antibody-virus)
   - Validation: Do misfolded proteins in ALS show "failed handshakes" with chaperones similar to Dengue NS1-antibody misrecognition?

3. **PTM-Centric Cross-Disease (RA → ALS/PD/Dengue)**
   - RA PTM database (citrullination, 30+ modifications) provides ground truth for PTM-induced structural changes
   - Tool: Goldilocks validation, AlphaFold3 PTM impact
   - Validation: Do ALS/Dengue PTMs cluster with RA PTMs in p-adic space?

---

## 2. Disease-Specific Research Frameworks

### 2.1 ALS (Amyotrophic Lateral Sclerosis)

#### 2.1.1 Background & Hypothesis

**Key Proteins:** TDP-43 (TAR DNA-binding protein 43), SOD1 (superoxide dismutase 1), FUS (fused in sarcoma), C9ORF72

**Pathology:** Motor neuron degeneration, protein aggregation, neuroinflammation

**Hypothesis:** Motor neurons have high protein synthesis demands. Codon usage bias in ALS-associated genes may:
1. Affect translation speed → co-translational folding efficiency
2. Influence PTM timing (phosphorylation during ribosome transit)
3. Trigger aggregation if translation stalls at non-optimal codons

#### 2.1.2 Research Questions

| Priority | Question | Method | Existing Infrastructure |
|:--------:|----------|--------|-------------------------|
| **1** | Do ALS genes show distinct codon usage bias in motor neurons vs other tissues? | RNA-seq codon frequency + TrainableCodonEncoder | `extremophile_codons.py` logic |
| **2** | Does TDP-43 codon usage correlate with phosphorylation site accessibility? | Codon position analysis + PTM sweep | `01_tau_phospho_sweep.py` adapted |
| **3** | Can p-adic distance predict TDP-43 aggregation propensity for variants? | Variant embedding + aggregation assays | Contact prediction framework |
| **4** | Do ALS genetic modifiers (SMN, FUS) show PPI network clustering? | Protein-protein interaction analysis | HolographicEncoder |
| **5** | Does immune infiltration correlate with TDP-43 epitope presentation? | HLA-peptide binding prediction | RA HLA scripts (01-04) |

#### 2.1.3 Data Acquisition Strategy

**Public Datasets:**
1. **GTEx (Genotype-Tissue Expression)** - Motor cortex RNA-seq
   - URL: https://gtexportal.org/
   - Use: Codon usage bias in healthy vs ALS-risk tissues

2. **ALS Data Portal** - Patient genomics + transcriptomics
   - URL: https://als.org/research/resources-for-researchers
   - Use: ALS-associated gene variants

3. **PhosphoSitePlus** - TDP-43/SOD1 phosphorylation sites
   - URL: https://www.phosphosite.org/
   - Use: PTM database (like tau 47 phospho-sites)

4. **UniProt** - TDP-43 (Q13148), SOD1 (P00441), FUS (P35637)
   - Use: Sequence, PTM annotations, disease variants

5. **PDB** - TDP-43 RNA recognition motif (4BS2), SOD1 structures
   - Use: AlphaFold3 validation targets

**Processed Data Needed:**
- ALS patient RNA-seq (GEO database, ~50 samples)
- Healthy motor neuron RNA-seq (GTEx, ~30 samples)
- TDP-43 variant aggregation kinetics (literature curation)

#### 2.1.4 Implementation Scripts

**Proposed File Structure:**
```
src/research/bioinformatics/codon_encoder_research/als/
├── data/
│   ├── tdp43_ptm_database.py          # Like tau_phospho_database.py
│   ├── sod1_variants.json              # Literature-curated variants
│   ├── als_genetic_modifiers.json      # PPI network data
│   └── motor_neuron_codon_bias.csv     # GTEx processed data
├── scripts/
│   ├── 01_als_codon_bias_analysis.py   # Motor neuron vs other tissues
│   ├── 02_tdp43_ptm_sweep.py           # Phospho/ubiquitin sites
│   ├── 03_aggregation_propensity.py    # VAE trajectory analysis
│   ├── 04_genetic_modifier_network.py  # HolographicEncoder PPI
│   ├── 05_neuroinflammation_epitopes.py # HLA-peptide binding
│   └── 06_alphafold3_misfolding.py     # Structure prediction
├── results/
│   ├── codon_bias/                     # Tissue-specific codon preferences
│   ├── ptm_analysis/                   # TDP-43 PTM impacts
│   ├── aggregation/                    # Trajectory + propensity scores
│   ├── ppi_network/                    # Genetic modifier interactions
│   └── immune_epitopes/                # HLA-DRB1 predictions
└── docs/
    ├── ALS_RESEARCH_SUMMARY.md
    └── TDP43_PTM_VALIDATION.md
```

**Script 01: ALS Codon Bias Analysis**
```python
# 01_als_codon_bias_analysis.py
from src.encoders import TrainableCodonEncoder
from src.core.padic_math import padic_valuation
import pandas as pd

# Load GTEx motor neuron RNA-seq
motor_neuron_counts = load_gtex_codon_counts('motor_cortex')
other_tissue_counts = load_gtex_codon_counts('cerebellum')

# Compute codon usage bias for ALS genes
als_genes = ['TARDBP', 'SOD1', 'FUS', 'C9ORF72']
for gene in als_genes:
    # Extract codon frequencies
    freq_motor = codon_frequency(motor_neuron_counts, gene)
    freq_other = codon_frequency(other_tissue_counts, gene)

    # Compute p-adic valuation bias
    for codon, freq in freq_motor.items():
        v_motor = padic_valuation(codon_to_index(codon), p=3)
        v_other = padic_valuation(codon_to_index(codon), p=3)

        # Optimal codons (v=0) should be enriched in motor neurons
        if v_motor == 0:
            enrichment = freq_motor[codon] / freq_other[codon]
            print(f"{gene} {codon}: Enrichment = {enrichment:.2f}")
```

**Script 02: TDP-43 PTM Sweep** (Adapted from tau framework)
```python
# 02_tdp43_ptm_sweep.py
from research.codon_encoder.pipelines.ptm_mapping import PTMMapper
from src.encoders import TrainableCodonEncoder

# TDP-43 phosphorylation sites (literature-curated)
TDP43_PHOSPHO_SITES = {
    403: {'residue': 'S', 'type': 'phosphorylation', 'pathology': 'aggregation'},
    409: {'residue': 'S', 'type': 'phosphorylation', 'pathology': 'nuclear_export'},
    410: {'residue': 'S', 'type': 'phosphorylation', 'pathology': 'aggregation'},
    # ... 20+ sites from PhosphoSitePlus
}

encoder = TrainableCodonEncoder.from_checkpoint('research/codon-encoder/training/results/trained_codon_encoder.pt')
mapper = PTMMapper(encoder)

tdp43_seq = get_uniprot_sequence('Q13148')
for position, ptm_info in TDP43_PHOSPHO_SITES.items():
    # Compare WT vs phosphorylated
    impact = mapper.compute_ptm_impact(tdp43_seq, position, ptm_info['type'])

    # Check if pathological sites cluster in p-adic space
    if ptm_info['pathology'] == 'aggregation':
        aggregation_score = compute_aggregation_propensity(impact)
        print(f"Position {position}: Aggregation score = {aggregation_score:.3f}")
```

#### 2.1.5 Expected Outcomes & Validation

| Analysis | Expected Finding | Validation Metric | Success Criterion |
|----------|------------------|-------------------|-------------------|
| Codon bias | Motor neurons enrich optimal codons (v=0) for ALS genes | Fold enrichment > 1.5 | p < 0.05 (Mann-Whitney) |
| PTM sweep | Aggregation-prone sites cluster in p-adic space | Silhouette score > 0.3 | Visual separation in UMAP |
| Aggregation | P-adic distance predicts aggregation kinetics | Spearman ρ > 0.5 | Literature aggregation rates |
| PPI network | Genetic modifiers show hub-like clustering | Network modularity > 0.4 | STRING database validation |
| Immune epitopes | TDP-43 epitopes overlap with microglial HLA alleles | Binding affinity < 500 nM | NetMHCIIpan predictions |

---

### 2.2 Parkinson's Disease

#### 2.2.1 Background & Hypothesis

**Key Proteins:** Alpha-synuclein (SNCA), LRRK2 (leucine-rich repeat kinase 2), Parkin (PARK2), DJ-1 (PARK7)

**Pathology:** Dopaminergic neuron loss, Lewy body formation (alpha-synuclein aggregates), neuroinflammation

**Hypothesis:** Alpha-synuclein aggregation is modulated by:
1. Codon usage affecting co-translational folding
2. S129 phosphorylation (90% of Lewy body alpha-synuclein is phosphorylated)
3. Membrane interaction requiring lipid modifications

**Parkinson's-Specific Aspect:** Dopaminergic neurons are metabolically stressed (dopamine oxidation), making them sensitive to protein quality control failures.

#### 2.2.2 Research Questions

| Priority | Question | Method | Existing Infrastructure |
|:--------:|----------|--------|-------------------------|
| **1** | Does alpha-synuclein codon usage differ in substantia nigra vs other brain regions? | RNA-seq codon bias analysis | GTEx + `01_als_codon_bias_analysis.py` adapted |
| **2** | Does S129 phosphorylation correlate with codon position effects? | PTM sweep + codon context | `02_tdp43_ptm_sweep.py` adapted |
| **3** | Can p-adic embeddings predict A30P/A53T/E46K aggregation propensity? | Variant embedding distance | TrainableCodonEncoder |
| **4** | Do alpha-synuclein epitopes trigger microglial activation via HLA-DR? | HLA-peptide binding | RA HLA scripts |
| **5** | Does LRRK2 kinase activity correlate with p-adic distance to substrates? | Substrate network analysis | HolographicEncoder |

#### 2.2.3 Data Acquisition Strategy

**Public Datasets:**
1. **GTEx** - Substantia nigra RNA-seq (dopaminergic neurons)
2. **UniProt** - Alpha-synuclein (P37840), LRRK2 (Q5S007)
3. **PhosphoSitePlus** - S129 phosphorylation + other alpha-synuclein PTMs
4. **PDB** - Alpha-synuclein fibril structures (6A6B, 6SSX, 6SST)
5. **MitoMiner** - Mitochondrial localization (Parkin, DJ-1)

**Parkinson's Patient Data:**
- PPMI (Parkinson's Progression Markers Initiative) - genomics
- GEO database - transcriptomics from post-mortem substantia nigra

#### 2.2.4 Implementation Scripts

**Proposed File Structure:**
```
src/research/bioinformatics/codon_encoder_research/parkinsons/
├── data/
│   ├── alpha_synuclein_ptm_database.py  # S129 + lipid modifications
│   ├── parkinsons_variants.json         # A30P, A53T, E46K, etc.
│   ├── lrrk2_substrates.json            # Kinase substrate network
│   └── substantia_nigra_codon_bias.csv  # GTEx processed
├── scripts/
│   ├── 01_parkinsons_codon_bias.py      # Dopaminergic neuron analysis
│   ├── 02_alpha_synuclein_ptm_sweep.py  # S129 phosphorylation focus
│   ├── 03_variant_aggregation.py        # A30P/A53T/E46K embeddings
│   ├── 04_microglial_epitopes.py        # HLA-DR presentation
│   ├── 05_lrrk2_substrate_network.py    # Kinase-substrate p-adic distances
│   └── 06_alphafold3_fibril_validation.py
├── results/
└── docs/
```

**Script 02: Alpha-Synuclein PTM Sweep**
```python
# 02_alpha_synuclein_ptm_sweep.py
ALPHA_SYN_PTM_SITES = {
    129: {'residue': 'S', 'type': 'phosphorylation', 'pathology': 'lewy_body', 'frequency': 0.90},
    87: {'residue': 'Y', 'type': 'phosphorylation', 'pathology': 'membrane_binding'},
    125: {'residue': 'S', 'type': 'phosphorylation', 'pathology': 'aggregation'},
    # Lipid modifications
    1: {'residue': 'M', 'type': 'acetylation', 'pathology': 'membrane_targeting'},
}

# Compare WT vs S129-phosphorylated alpha-synuclein
alpha_syn_seq = get_uniprot_sequence('P37840')
mapper = PTMMapper(encoder)

# Key question: Does S129 phosphorylation change membrane affinity?
for position, ptm_info in ALPHA_SYN_PTM_SITES.items():
    impact = mapper.compute_ptm_impact(alpha_syn_seq, position, ptm_info['type'])

    # Compare to membrane interaction domains (residues 1-60, 61-95)
    membrane_domain_distance = compute_padic_distance(impact, membrane_region_embedding)
    print(f"S{position}: Membrane domain distance = {membrane_domain_distance:.3f}")
```

#### 2.2.5 Cross-Validation with ALS

**Shared Mechanisms to Test:**
1. **Protein Aggregation:** TDP-43 (ALS) vs Alpha-synuclein (PD) - Do they show similar p-adic trajectory patterns?
2. **Neuroinflammation:** Do ALS TDP-43 epitopes and PD alpha-synuclein epitopes cluster in HLA-DR binding space?
3. **Codon Bias:** Motor neurons vs dopaminergic neurons - Different optimization strategies?

**Implementation:**
```python
# Cross-disease aggregation comparison
from scripts.als.03_aggregation_propensity import compute_als_trajectory
from scripts.parkinsons.03_variant_aggregation import compute_pd_trajectory

# Do aggregation-prone proteins follow similar trajectories in VAE space?
als_trajectory = compute_als_trajectory(tdp43_variants)
pd_trajectory = compute_pd_trajectory(alpha_syn_variants)

# Compute trajectory similarity
trajectory_distance = poincare_distance(als_trajectory, pd_trajectory)
print(f"ALS-PD aggregation trajectory distance: {trajectory_distance:.3f}")

# If distance < 3.0, they share aggregation mechanisms
if trajectory_distance < 3.0:
    print("Shared aggregation mechanism detected - validate with cross-disease therapeutics")
```

---

### 2.3 Dengue Hemorrhagic Fever (DHF)

#### 2.3.1 Background & Hypothesis

**Key Proteins:** NS1 (non-structural protein 1), E protein (envelope), prM (precursor membrane)

**Pathology:** Secondary infection with heterologous serotype → Antibody-Dependent Enhancement (ADE) → immune cell infection → cytokine storm → vascular leak → hemorrhagic fever

**Hypothesis:** Immune cell "handshake" failures in Dengue DHF parallel protein-protein interaction failures in neurodegeneration:
1. Non-neutralizing antibodies from primary infection bind NS1/E protein from secondary infection
2. Fc receptor engagement on immune cells → viral entry instead of neutralization
3. PTM differences between serotypes may modulate antibody recognition

**Connection to Neurology:** Immune cell receptor-ligand interactions are analogous to neurotransmitter receptor binding. Both require precise codon-encoded structure.

#### 2.3.2 Research Questions

| Priority | Question | Method | Existing Infrastructure |
|:--------:|----------|--------|-------------------------|
| **1** | Do serotype-specific NS1 PTMs correlate with DHF severity? | PTM sweep across 4 serotypes | RA PTM database + HIV escape analysis |
| **2** | Can p-adic distance predict ADE risk for serotype combinations? | Secondary infection risk modeling | HIV immune escape framework |
| **3** | Do NS1 glycosylation patterns cluster in p-adic space by severity? | Glycan shield analysis | HIV glycan_shield research |
| **4** | Does HLA-DR presentation of NS1 epitopes differ between mild vs severe cases? | HLA-peptide binding | RA HLA scripts |
| **5** | Can trajectory forecasting predict DHF outbreaks from sequence evolution? | Serotype trajectory + immune memory | Rojas trajectory forecasting |

#### 2.3.3 Data Acquisition Strategy

**Public Datasets:**
1. **NCBI Virus** - Dengue genome sequences (2011-2024, Paraguay focus)
2. **UniProt** - NS1 protein (serotype-specific entries)
3. **ViPR (Virus Pathogen Resource)** - Dengue functional genomics
4. **PDB** - NS1 hexamer structure (4O6B), E protein (1OKE)
5. **IEDB (Immune Epitope Database)** - Dengue epitopes + HLA binding

**Clinical Data Needed:**
- DHF patient serotype history (primary vs secondary infection)
- Severity classification (dengue fever vs DHF vs dengue shock syndrome)
- Geographic/temporal outbreak data

#### 2.3.4 Implementation Scripts

**Proposed File Structure:**
```
deliverables/partners/alejandra_rojas/dengue_dhf/
├── data/
│   ├── ns1_ptm_database.py              # Glycosylation sites (N130, N207, etc.)
│   ├── serotype_sequences.fasta         # DENV1-4 from Paraguay
│   ├── ade_risk_matrix.csv              # Primary × Secondary combinations
│   └── dhf_patient_metadata.json        # Severity + serotype history
├── scripts/
│   ├── 01_ns1_ptm_sweep.py              # Glycosylation across serotypes
│   ├── 02_ade_risk_prediction.py        # Secondary infection modeling
│   ├── 03_glycan_shield_analysis.py     # HIV framework adapted
│   ├── 04_hla_epitope_presentation.py   # Immune recognition
│   ├── 05_dhf_outbreak_forecasting.py   # Trajectory + severity
│   └── 06_alphafold3_antibody_complex.py # NS1-antibody structures
├── results/
│   ├── ptm_analysis/                    # Serotype PTM differences
│   ├── ade_risk/                        # Risk scores per combination
│   ├── glycan_shield/                   # Immune evasion patterns
│   ├── hla_binding/                     # Epitope predictions
│   └── outbreak_forecast/               # Geographic risk maps
└── docs/
    ├── DENGUE_DHF_RESEARCH_SUMMARY.md
    └── ADE_PREDICTION_VALIDATION.md
```

**Script 01: NS1 PTM Sweep**
```python
# 01_ns1_ptm_sweep.py
from research.codon_encoder.pipelines.ptm_mapping import PTMMapper

# NS1 glycosylation sites (key for immune evasion)
NS1_GLYCOSYLATION_SITES = {
    130: {'type': 'N-glycosylation', 'serotype_specificity': 'DENV1/2'},
    207: {'type': 'N-glycosylation', 'serotype_specificity': 'All'},
    # ... additional sites from literature
}

# Compare NS1 sequences from DHF vs dengue fever patients
dhf_sequences = load_dhf_patient_sequences('severe')
df_sequences = load_dhf_patient_sequences('mild')

for serotype in ['DENV1', 'DENV2', 'DENV3', 'DENV4']:
    dhf_ns1 = get_ns1_sequence(dhf_sequences, serotype)
    df_ns1 = get_ns1_sequence(df_sequences, serotype)

    # Compute PTM impact for each glycosylation site
    for position, glycan_info in NS1_GLYCOSYLATION_SITES.items():
        dhf_impact = mapper.compute_ptm_impact(dhf_ns1, position, 'glycosylation')
        df_impact = mapper.compute_ptm_impact(df_ns1, position, 'glycosylation')

        # Do severe cases have different glycan patterns?
        impact_distance = padic_distance(dhf_impact, df_impact)
        print(f"{serotype} N{position}: DHF vs DF distance = {impact_distance:.3f}")
```

**Script 02: ADE Risk Prediction** (HIV immune escape framework adapted)
```python
# 02_ade_risk_prediction.py
from src.research.bioinformatics.codon_encoder_research.hiv.analyze_ctl_escape_expanded import compute_cluster_boundary_crossing

# Antibody-Dependent Enhancement risk matrix
# Primary infection → memory antibodies → Secondary infection
ADE_COMBINATIONS = [
    {'primary': 'DENV1', 'secondary': 'DENV2', 'observed_dhf_rate': 0.15},
    {'primary': 'DENV2', 'secondary': 'DENV1', 'observed_dhf_rate': 0.08},
    # ... all 12 combinations (4 × 3)
]

# Hypothesis: ADE occurs when secondary serotype NS1 is in "Goldilocks zone"
# - Too similar → neutralizing antibodies work
# - Too different → no antibody binding
# - Just right → binding but not neutralizing (Fc-mediated entry)

for combo in ADE_COMBINATIONS:
    primary_ns1_emb = encoder.encode_sequence(get_ns1_seq(combo['primary']))
    secondary_ns1_emb = encoder.encode_sequence(get_ns1_seq(combo['secondary']))

    # Compute p-adic distance
    ade_distance = poincare_distance(primary_ns1_emb, secondary_ns1_emb)

    # Check if distance is in Goldilocks zone (5.8-6.9 from HIV CTL escape)
    if 5.8 <= ade_distance <= 6.9:
        predicted_ade_risk = 'HIGH'
    else:
        predicted_ade_risk = 'LOW'

    # Validate against observed DHF rate
    print(f"{combo['primary']}→{combo['secondary']}: Distance={ade_distance:.2f}, "
          f"Predicted={predicted_ade_risk}, Observed rate={combo['observed_dhf_rate']:.2%}")
```

#### 2.3.5 Cross-Validation with Neurological Diseases

**Shared Mechanisms to Test:**

1. **Protein-Protein "Handshake" Failures:**
   - Dengue: Non-neutralizing antibody + NS1 → failed neutralization
   - ALS: Misfolded TDP-43 + chaperone → failed refolding
   - Parkinson's: Alpha-synuclein + membrane receptor → failed clearance
   - **Test:** Do all three show similar p-adic distances in "failed handshake" zone?

2. **Immune Recognition:**
   - Dengue: HLA-DR presentation of NS1 epitopes
   - ALS: HLA-DR presentation of TDP-43 (neuroinflammation)
   - Parkinson's: HLA-DR presentation of alpha-synuclein (microglial activation)
   - **Test:** Do epitopes cluster by disease or by HLA allele?

3. **PTM-Driven Conformational Changes:**
   - Dengue: NS1 glycosylation affects antibody binding
   - ALS: TDP-43 phosphorylation triggers aggregation
   - Parkinson's: Alpha-synuclein S129 phosphorylation → Lewy bodies
   - **Test:** Do all PTMs show similar radial shifts in p-adic space?

**Implementation:**
```python
# Cross-disease "handshake failure" analysis
from scripts.dengue_dhf.02_ade_risk_prediction import compute_ade_goldilocks_zone
from scripts.als.04_genetic_modifier_network import compute_ppi_failure_distance
from scripts.parkinsons.05_lrrk2_substrate_network import compute_substrate_distance

# Compute "failed interaction" distances for each disease
dengue_failed_distance = compute_ade_goldilocks_zone('DENV1', 'DENV2')  # ADE zone
als_failed_distance = compute_ppi_failure_distance('TDP43', 'HSP70')    # Chaperone failure
pd_failed_distance = compute_substrate_distance('SNCA', 'LAMP2A')       # Clearance failure

# Do they cluster around the same p-adic distance?
failed_distances = [dengue_failed_distance, als_failed_distance, pd_failed_distance]
mean_failed_distance = np.mean(failed_distances)
std_failed_distance = np.std(failed_distances)

print(f"Cross-disease 'failed handshake' distance: {mean_failed_distance:.2f} ± {std_failed_distance:.2f}")

# If std < 1.5, there's a universal "failure zone" in p-adic space
if std_failed_distance < 1.5:
    print("UNIVERSAL HANDSHAKE FAILURE ZONE DETECTED")
    print("This suggests p-adic geometry encodes fundamental protein interaction rules")
```

---

## 3. Unified Cross-Disease Validation Framework

### 3.1 PTM-Centric Integration

**Unified PTM Database Structure:**

```python
# unified_ptm_database.py
CROSS_DISEASE_PTM_DATABASE = {
    'rheumatoid_arthritis': {
        'citrullination': 47 sites,  # Existing RA data
        'proteins': ['Vimentin', 'Fibrinogen', 'Collagen II']
    },
    'alzheimers': {
        'phosphorylation': 47 sites,  # Tau framework
        'proteins': ['Tau', 'APP', 'Presenilin']
    },
    'als': {
        'phosphorylation': 20+ sites,  # Proposed TDP-43
        'ubiquitination': 10+ sites,
        'proteins': ['TDP-43', 'SOD1', 'FUS']
    },
    'parkinsons': {
        'phosphorylation': 10+ sites,  # Proposed alpha-synuclein
        'ubiquitination': 5+ sites,
        'lipidation': 2 sites,
        'proteins': ['Alpha-synuclein', 'LRRK2', 'Parkin']
    },
    'dengue_dhf': {
        'glycosylation': 5+ sites,  # Proposed NS1
        'proteins': ['NS1', 'E protein', 'prM']
    }
}
```

**Cross-Disease PTM Clustering Analysis:**

```python
# Embed all PTMs in unified p-adic space
all_ptm_embeddings = []
all_ptm_labels = []

for disease, ptm_data in CROSS_DISEASE_PTM_DATABASE.items():
    for protein in ptm_data['proteins']:
        for ptm_site in get_ptm_sites(protein):
            embedding = mapper.compute_ptm_impact(protein_seq, ptm_site, ptm_type)
            all_ptm_embeddings.append(embedding)
            all_ptm_labels.append({'disease': disease, 'protein': protein, 'type': ptm_type})

# Cluster in p-adic space
from sklearn.cluster import AgglomerativeClustering
clustering = AgglomerativeClustering(n_clusters=5, metric='precomputed')
distance_matrix = compute_pairwise_padic_distances(all_ptm_embeddings)
clusters = clustering.fit_predict(distance_matrix)

# Analyze cluster composition
for cluster_id in range(5):
    cluster_members = [label for i, label in enumerate(all_ptm_labels) if clusters[i] == cluster_id]
    disease_composition = count_by_disease(cluster_members)
    print(f"Cluster {cluster_id}: {disease_composition}")

    # If diseases mix in clusters → shared PTM mechanisms
    # If diseases segregate → disease-specific PTM effects
```

### 3.2 Immune Recognition Cross-Validation

**Unified HLA-Peptide Binding Analysis:**

All three diseases involve immune recognition:
- **Dengue DHF:** NS1 epitopes presented to T cells
- **ALS:** TDP-43 epitopes → microglial activation → neuroinflammation
- **Parkinson's:** Alpha-synuclein epitopes → microglial activation

**Shared Analysis Pipeline:**

```python
# Cross-disease HLA-DR epitope analysis
from src.research.bioinformatics.codon_encoder_research.rheumatoid_arthritis.scripts.01_analyze_hla_peptide_binding import predict_hla_binding

CROSS_DISEASE_EPITOPES = {
    'dengue': extract_ns1_epitopes(),
    'als': extract_tdp43_epitopes(),
    'parkinsons': extract_alpha_syn_epitopes()
}

# For each HLA-DRB1 allele common in populations
common_hla_alleles = ['DRB1*01:01', 'DRB1*04:01', 'DRB1*15:01']

for allele in common_hla_alleles:
    for disease, epitopes in CROSS_DISEASE_EPITOPES.items():
        binding_scores = predict_hla_binding(epitopes, allele)

        # Strong binders (< 500 nM) may trigger immune response
        strong_binders = [ep for ep in epitopes if binding_scores[ep] < 500]

        print(f"{disease} + {allele}: {len(strong_binders)} strong binders")

        # Embed strong binders in p-adic space
        binder_embeddings = [encoder.encode_sequence(ep) for ep in strong_binders]

        # Do epitopes from different diseases cluster together?
        # This would suggest shared immune recognition patterns

# Statistical test: Do epitopes cluster by disease or by HLA allele?
from scipy.stats import chi2_contingency
contingency_table = build_cluster_disease_table(clusters, diseases)
chi2, p_value = chi2_contingency(contingency_table)

if p_value < 0.05:
    print("Epitopes cluster by disease (disease-specific immune signatures)")
else:
    print("Epitopes cluster by HLA allele (allele-specific recognition patterns)")
```

### 3.3 Codon Bias Cross-Tissue Validation

**Neurological Tissue Specificity:**

Test if tissue-specific codon usage correlates with disease susceptibility:

```python
# Cross-tissue codon bias comparison
TISSUE_DISEASE_MAP = {
    'motor_cortex': 'ALS',
    'substantia_nigra': 'Parkinsons',
    'immune_cells': 'Dengue_DHF'
}

# Load GTEx RNA-seq for each tissue
for tissue, disease in TISSUE_DISEASE_MAP.items():
    tissue_codon_bias = compute_tissue_codon_bias(tissue)

    # Disease-associated genes
    disease_genes = get_disease_genes(disease)

    # Do disease genes show codon optimization for their tissue?
    for gene in disease_genes:
        gene_codon_usage = get_gene_codon_usage(gene)

        # Adaptation index: how well does gene match tissue bias?
        adaptation = compute_adaptation_index(gene_codon_usage, tissue_codon_bias)

        print(f"{disease} {gene} in {tissue}: Adaptation = {adaptation:.3f}")

        # Hypothesis: Low adaptation → translation stress → disease risk
        if adaptation < 0.3:
            print(f"  WARNING: {gene} poorly adapted to {tissue}")

# Cross-disease comparison: Are neurological tissues (motor cortex, SN) more similar to each other than to immune cells?
motor_cortex_bias = compute_tissue_codon_bias('motor_cortex')
substantia_nigra_bias = compute_tissue_codon_bias('substantia_nigra')
immune_cells_bias = compute_tissue_codon_bias('immune_cells')

neuro_distance = codon_bias_distance(motor_cortex_bias, substantia_nigra_bias)
neuro_immune_distance = codon_bias_distance(motor_cortex_bias, immune_cells_bias)

print(f"Neurological tissue similarity: {neuro_distance:.3f}")
print(f"Neuro-immune distance: {neuro_immune_distance:.3f}")

# If neuro_distance << neuro_immune_distance → neurological tissues share codon preferences
```

### 3.4 Contact Prediction for Protein Interactions

**Apply Small Protein Conjecture to Disease Proteins:**

The contact prediction framework (AUC 0.586-0.814 for small proteins) can validate protein-protein interactions:

```python
# Apply contact prediction to disease PPIs
from research.contact_prediction.scripts.01_test_real_protein import predict_contacts

DISEASE_PPI_PAIRS = [
    {'protein1': 'TDP-43', 'protein2': 'HSP70', 'disease': 'ALS', 'expected_interaction': True},
    {'protein1': 'Alpha-synuclein', 'protein2': 'LAMP2A', 'disease': 'Parkinsons', 'expected_interaction': True},
    {'protein1': 'NS1', 'protein2': 'Antibody_Fc', 'disease': 'Dengue', 'expected_interaction': True},
]

for ppi in DISEASE_PPI_PAIRS:
    # Predict contacts between protein1 and protein2
    contacts = predict_contacts(ppi['protein1'], ppi['protein2'])

    # Compute AUC vs known interfaces (from PDB or AlphaFold-Multimer)
    known_interface = get_known_interface(ppi['protein1'], ppi['protein2'])
    auc = compute_contact_auc(contacts, known_interface)

    print(f"{ppi['disease']} {ppi['protein1']}-{ppi['protein2']}: AUC = {auc:.3f}")

    # If AUC > 0.6 → p-adic geometry captures interaction
    # If AUC < 0.55 → interaction may be disease-disrupted (failed handshake)

    if auc < 0.55 and ppi['expected_interaction']:
        print(f"  FAILED HANDSHAKE DETECTED in {ppi['disease']}")
```

---

## 4. Implementation Roadmap

### Phase 1: Foundation (Weeks 1-4)

**Week 1: Data Acquisition & Environment Setup**
- [ ] Download GTEx motor cortex & substantia nigra RNA-seq
- [ ] Curate TDP-43, SOD1, alpha-synuclein PTM databases (PhosphoSitePlus)
- [ ] Download Dengue NS1 sequences for all 4 serotypes (NCBI Virus)
- [ ] Set up research directories (als/, parkinsons/, dengue_dhf/)

**Week 2: ALS Codon Bias Analysis (P1 Question)**
- [ ] Implement `01_als_codon_bias_analysis.py`
- [ ] Compare motor neuron vs other tissue codon usage for TARDBP, SOD1, FUS
- [ ] Compute p-adic valuation enrichment (v=0 optimal codons)
- [ ] Validate: Fold enrichment > 1.5, p < 0.05
- [ ] **Deliverable:** ALS codon bias report

**Week 3: Parkinson's Codon Bias Analysis**
- [ ] Implement `01_parkinsons_codon_bias.py`
- [ ] Compare substantia nigra vs cerebellum for SNCA, LRRK2, PARK2
- [ ] Test correlation between codon usage and S129 phosphorylation
- [ ] **Deliverable:** Parkinson's codon bias report

**Week 4: Dengue NS1 PTM Sweep**
- [ ] Implement `01_ns1_ptm_sweep.py`
- [ ] Map glycosylation sites for all 4 serotypes
- [ ] Compare DHF vs dengue fever patient sequences
- [ ] **Deliverable:** NS1 PTM analysis results

**Phase 1 Milestone:** Codon bias validated in neurological tissues + Dengue PTM baseline

---

### Phase 2: PTM Analysis & Cross-Disease Clustering (Weeks 5-8)

**Week 5: ALS TDP-43 PTM Sweep**
- [ ] Implement `02_tdp43_ptm_sweep.py` (adapted from tau framework)
- [ ] Analyze 20+ phosphorylation sites from PhosphoSitePlus
- [ ] Compute aggregation propensity scores
- [ ] **Deliverable:** TDP-43 PTM impact analysis

**Week 6: Parkinson's Alpha-Synuclein PTM Sweep**
- [ ] Implement `02_alpha_synuclein_ptm_sweep.py`
- [ ] Focus on S129 phosphorylation + lipid modifications
- [ ] Compare to membrane interaction domains
- [ ] **Deliverable:** Alpha-synuclein PTM impact analysis

**Week 7: Unified PTM Database Integration**
- [ ] Create `unified_ptm_database.py`
- [ ] Integrate RA (47 citrullination), Tau (47 phospho), ALS, PD, Dengue
- [ ] Implement cross-disease PTM clustering analysis
- [ ] **Deliverable:** Unified PTM clustering results

**Week 8: PTM Cluster Validation**
- [ ] Analyze cluster composition (disease-specific vs shared)
- [ ] Compare to RA Goldilocks validation framework
- [ ] Test if ALS/PD/Dengue PTMs show similar structural impacts
- [ ] **Deliverable:** Cross-disease PTM validation report

**Phase 2 Milestone:** Unified PTM database with cross-disease clustering analysis

---

### Phase 3: Immune Recognition & HLA Binding (Weeks 9-12)

**Week 9: ALS Neuroinflammation Epitopes**
- [ ] Implement `05_neuroinflammation_epitopes.py`
- [ ] Predict HLA-DR binding for TDP-43 epitopes
- [ ] Compare to microglial activation markers
- [ ] **Deliverable:** ALS immune epitope predictions

**Week 10: Parkinson's Microglial Epitopes**
- [ ] Implement `04_microglial_epitopes.py`
- [ ] Predict HLA-DR binding for alpha-synuclein epitopes
- [ ] Focus on A30P/A53T/E46K variants
- [ ] **Deliverable:** Parkinson's immune epitope predictions

**Week 11: Dengue DHF HLA Binding**
- [ ] Implement `04_hla_epitope_presentation.py`
- [ ] Analyze NS1 epitopes across 4 serotypes
- [ ] Correlate with DHF severity data
- [ ] **Deliverable:** Dengue HLA binding analysis

**Week 12: Cross-Disease Immune Recognition Validation**
- [ ] Implement unified HLA-peptide clustering
- [ ] Test if epitopes cluster by disease or HLA allele
- [ ] Compare to HIV/RA immune escape frameworks
- [ ] **Deliverable:** Cross-disease immune recognition report

**Phase 3 Milestone:** HLA-DR epitope maps for all 3 diseases + cross-validation

---

### Phase 4: Protein Interaction Networks & Structural Validation (Weeks 13-16)

**Week 13: ALS PPI Network Analysis**
- [ ] Implement `04_genetic_modifier_network.py`
- [ ] Use HolographicEncoder for SMN, FUS, C9ORF72 interactions
- [ ] Identify "failed handshake" distances for chaperone interactions
- [ ] **Deliverable:** ALS PPI network results

**Week 14: Parkinson's Substrate Network**
- [ ] Implement `05_lrrk2_substrate_network.py`
- [ ] Map LRRK2 kinase-substrate interactions in p-adic space
- [ ] Test substrate distance correlations
- [ ] **Deliverable:** Parkinson's substrate network

**Week 15: Dengue ADE Risk Prediction**
- [ ] Implement `02_ade_risk_prediction.py`
- [ ] Test Goldilocks zone hypothesis (5.8-6.9 from HIV)
- [ ] Validate against observed DHF rates for serotype combinations
- [ ] **Deliverable:** ADE risk matrix with predictions

**Week 16: Cross-Disease "Handshake Failure" Analysis**
- [ ] Implement unified handshake failure comparison
- [ ] Test if ALS chaperone, PD clearance, Dengue ADE show similar p-adic distances
- [ ] Compute universal failure zone
- [ ] **Deliverable:** Universal handshake failure zone report

**Phase 4 Milestone:** Protein interaction networks + universal failure mechanism

---

### Phase 5: AlphaFold3 Structural Validation (Weeks 17-20)

**Week 17: ALS Misfolded Structures**
- [ ] Implement `06_alphafold3_misfolding.py`
- [ ] Predict TDP-43 WT vs phosphorylated structures
- [ ] Compare to known aggregation-prone conformations
- [ ] **Deliverable:** ALS structural validation results

**Week 18: Parkinson's Fibril Structures**
- [ ] Implement `06_alphafold3_fibril_validation.py`
- [ ] Predict alpha-synuclein WT vs S129-phosphorylated
- [ ] Compare to known Lewy body fibril structures (PDB 6A6B)
- [ ] **Deliverable:** Parkinson's structural validation

**Week 19: Dengue Antibody Complexes**
- [ ] Implement `06_alphafold3_antibody_complex.py`
- [ ] Predict NS1-antibody complexes for ADE vs neutralizing
- [ ] Validate against known NS1 structures (PDB 4O6B)
- [ ] **Deliverable:** Dengue antibody complex predictions

**Week 20: Cross-Disease Structural Comparison**
- [ ] Compare PTM-induced conformational changes across diseases
- [ ] Test if p-adic radial shifts correlate with RMSD
- [ ] Validate contact predictions with AlphaFold interfaces
- [ ] **Deliverable:** Cross-disease structural validation report

**Phase 5 Milestone:** AlphaFold3 validation for all 3 diseases + structural cross-validation

---

### Phase 6: Integration & Publication (Weeks 21-24)

**Week 21: Alejandra Rojas Package Extensions**
- [ ] Integrate Dengue DHF analysis into existing arbovirus package
- [ ] Add ADE risk prediction module
- [ ] Extend trajectory forecasting to include severity predictions
- [ ] **Deliverable:** Updated Rojas package with DHF capabilities

**Week 22: Cross-Disease Validation Dashboard**
- [ ] Create visualization dashboard for all findings
- [ ] Include PTM clustering, immune recognition, handshake failures
- [ ] Interactive plots for exploring disease connections
- [ ] **Deliverable:** Cross-disease validation dashboard

**Week 23: Manuscript Preparation**
- [ ] Write comprehensive research paper
- [ ] Title: "P-adic Codon Embeddings Reveal Universal Mechanisms in Neurological and Immune Diseases"
- [ ] Sections: Introduction, Methods, Results (5 phases), Discussion, Conclusion
- [ ] **Deliverable:** Draft manuscript

**Week 24: Supplementary Materials & Code Release**
- [ ] Prepare supplementary tables (PTM database, epitope predictions)
- [ ] Clean and document all code
- [ ] Create tutorial notebooks for reproduction
- [ ] **Deliverable:** Publication-ready package

**Phase 6 Milestone:** Complete research package ready for publication

---

## 5. Expected Outcomes & Impact

### 5.1 Scientific Contributions

**Immediate (Phases 1-3):**
1. **First demonstration** of tissue-specific codon bias in ALS and Parkinson's
2. **Novel PTM database** integrating 5 diseases (RA, Alzheimer's, ALS, Parkinson's, Dengue)
3. **ADE risk predictor** for Dengue DHF based on p-adic distances

**Medium-term (Phases 4-5):**
4. **Universal protein interaction failure mechanism** across neurological and immune diseases
5. **Cross-disease immune recognition patterns** validated across ALS/PD/Dengue
6. **Structural validation** of p-adic predictions using AlphaFold3

**Long-term (Phase 6+):**
7. **Clinical decision support** for Dengue DHF risk assessment
8. **Drug repurposing** opportunities (if ALS/PD share mechanisms, shared therapeutics)
9. **Vaccine design** for Dengue (avoiding ADE-inducing epitopes)

### 5.2 Validation Metrics

| Outcome | Validation Metric | Success Criterion | Clinical Impact |
|---------|-------------------|-------------------|-----------------|
| Codon bias | Fold enrichment (v=0 codons) | > 1.5, p < 0.05 | Biomarker for disease risk |
| PTM clustering | Silhouette score | > 0.3 | PTM-targeted therapies |
| ADE prediction | Correlation with observed DHF rates | Spearman ρ > 0.6 | Outbreak preparedness |
| Epitope binding | NetMHCIIpan predicted affinity | < 500 nM for strong binders | Vaccine design |
| Handshake failure | Universal failure zone std | < 1.5 across diseases | Therapeutic target |
| Structural validation | Contact AUC vs AlphaFold | > 0.6 for interactions | Structure-based drug design |

### 5.3 Clinical Translation Pathways

**For Dengue DHF:**
- **Risk stratification:** Patients with primary DENV1 + circulating DENV2 → high ADE risk
- **Vaccine design:** Avoid epitopes in ADE Goldilocks zone (5.8-6.9 p-adic distance)
- **Surveillance:** Real-time forecasting integrates ADE risk into outbreak predictions

**For ALS:**
- **Early detection:** Screen for TDP-43 codon bias in patient transcriptomics
- **PTM biomarkers:** Phospho-TDP-43 patterns predict progression rate
- **Therapeutic targets:** Modulate PTMs to prevent aggregation (like RA Goldilocks)

**For Parkinson's:**
- **Genetic counseling:** Alpha-synuclein codon variants with high aggregation risk
- **Disease monitoring:** Track S129 phosphorylation trajectory in p-adic space
- **Immunotherapy:** Target alpha-synuclein epitopes outside microglial activation zone

### 5.4 Cross-Disease Therapeutic Opportunities

**If validation succeeds, test:**

1. **Chaperone enhancers** (ALS) → May help NS1 folding (Dengue) or alpha-synuclein clearance (PD)
2. **PTM inhibitors** (RA citrullination blockers) → May prevent TDP-43 aggregation (ALS) or Lewy body formation (PD)
3. **Immune modulators** (Dengue) → May reduce neuroinflammation (ALS/PD)

**Repurposing Candidates:**
- Metformin (LRRK2 inhibitor, PD) → Test in ALS (TDP-43 modulation)
- Rapamycin (autophagy inducer, PD) → Test in Dengue (viral clearance)

---

## 6. Risk Mitigation & Contingency Plans

### 6.1 Data Availability Risks

**Risk:** Insufficient ALS/PD patient RNA-seq data

**Mitigation:**
- Use published datasets from GEO/SRA (>100 ALS studies available)
- Focus on well-characterized variants (TDP-43 A315T, SOD1 A4V)
- If patient data limited, use cell line models (iPSC-derived motor neurons)

**Risk:** DHF severity data not linked to sequences

**Mitigation:**
- Use published Dengue cohorts (Vietnam, Brazil, Paraguay)
- Collaborate with epidemiologists (Alejandra Rojas contacts)
- Start with serotype-level analysis (less granular but still valuable)

### 6.2 Validation Risks

**Risk:** P-adic distances don't predict ADE risk

**Contingency:**
- Fall back to established antibody affinity models
- Use p-adic embeddings as features in ML predictor (ensemble approach)
- Still valuable for Rojas package (primer design, trajectory forecasting)

**Risk:** Cross-disease PTMs don't cluster

**Contingency:**
- Analyze diseases separately (still valuable for each disease)
- Test if clustering is PTM-type specific (e.g., all phosphorylation clusters together)
- Use as null hypothesis validation (diseases are truly distinct)

### 6.3 Timeline Risks

**Risk:** AlphaFold3 validation takes longer than 4 weeks

**Mitigation:**
- Parallelize structure predictions (use AlphaFold Server API)
- Prioritize key structures (TDP-43, alpha-synuclein, NS1)
- If needed, use existing PDB structures for initial validation

**Risk:** Full 24-week timeline not feasible

**Prioritization:**
- **Must-have (Weeks 1-12):** Codon bias + PTM analysis + HLA binding → Proves conjecture core
- **Nice-to-have (Weeks 13-20):** PPI networks + structural validation → Adds mechanistic depth
- **Publication (Weeks 21-24):** Can extend if Phases 1-5 require more time

---

## 7. Collaboration & Resource Allocation

### 7.1 Recommended Team Structure

**Lead Researcher (Full-time equivalent):**
- Oversees all 6 phases
- Writes manuscripts
- Coordinates with Alejandra Rojas

**Bioinformatician (0.5 FTE):**
- Data acquisition (GTEx, GEO, NCBI)
- Pipeline development
- Statistical validation

**Computational Biologist (0.5 FTE):**
- P-adic encoder training
- AlphaFold3 structure prediction
- Cross-disease integration

**Domain Experts (Consultants, 0.1 FTE each):**
- Neurologist (ALS/Parkinson's clinical context)
- Immunologist (Dengue DHF, HLA binding)
- Structural biologist (AlphaFold validation)

### 7.2 Computational Resources

**Training:**
- TrainableCodonEncoder already trained (no additional GPU time needed)
- AlphaFold3: Use AlphaFold Server (free) or Google Colab (medium structures ~2 hours)

**Data Storage:**
- GTEx RNA-seq: ~50 GB
- Dengue sequences: ~1 GB
- AlphaFold structures: ~10 GB
- Total: ~100 GB (cloud storage recommended)

**Analysis:**
- Most scripts run on CPU (p-adic distance computations are fast)
- GPU needed only for encoder inference (batch processing)

### 7.3 Budget Estimate (Optional, for grant proposals)

| Category | Item | Cost (USD) | Notes |
|----------|------|------------|-------|
| Personnel | Lead Researcher (6 months) | $60,000 | Postdoc or senior PhD student |
| Personnel | Bioinformatician (3 months) | $30,000 | Part-time contractor |
| Personnel | Computational Biologist (3 months) | $30,000 | Part-time contractor |
| Consultants | Domain experts (3 × 1 month) | $15,000 | $5,000 each |
| Compute | Cloud storage + compute | $2,000 | AWS/GCP credits |
| Publication | Open access fees | $3,000 | High-impact journal |
| **Total** | | **$140,000** | 6-month project |

---

## 8. Immediate Next Steps (Week 1 Action Items)

### 8.1 Data Acquisition Checklist

- [ ] **GTEx Portal:** Download motor cortex RNA-seq (BAM files or gene-level counts)
  - URL: https://gtexportal.org/home/datasets
  - Tissues: Brain - Frontal Cortex (BA9), Brain - Substantia nigra

- [ ] **GEO Database:** Search for ALS patient transcriptomics
  - Keywords: "ALS motor neuron RNA-seq", "TDP-43 patient"
  - Download: GSE124439, GSE67196 (known ALS studies)

- [ ] **PhosphoSitePlus:** Download PTM annotations
  - Proteins: TDP-43 (Q13148), Alpha-synuclein (P37840), SOD1 (P00441)
  - Export: CSV with positions, modification types, citations

- [ ] **NCBI Virus:** Download Dengue NS1 sequences
  - Filters: Dengue 1-4, complete genomes, Paraguay 2011-2024
  - Export: FASTA format

- [ ] **IEDB:** Download Dengue T-cell epitopes
  - Organism: Dengue virus
  - MHC restriction: HLA-DR
  - Export: CSV with epitope sequences, HLA alleles, assay results

### 8.2 Environment Setup

```bash
# Create research directories
mkdir -p src/research/bioinformatics/codon_encoder_research/als/{data,scripts,results,docs}
mkdir -p src/research/bioinformatics/codon_encoder_research/parkinsons/{data,scripts,results,docs}
mkdir -p deliverables/partners/alejandra_rojas/dengue_dhf/{data,scripts,results,docs}

# Install additional dependencies (if needed)
pip install gtfparse  # For GTEx processing
pip install pyvcf     # For genetic variants
pip install mhctools  # For HLA binding prediction
```

### 8.3 Initial Script Templates

Create initial script templates with TODO markers:

```python
# src/research/bioinformatics/codon_encoder_research/als/scripts/01_als_codon_bias_analysis.py

"""
ALS Codon Bias Analysis

Compares codon usage in motor neurons vs other tissues for ALS-associated genes.
Tests Hypothesis P1: Motor neurons show distinct codon bias.
"""

from src.encoders import TrainableCodonEncoder
from src.core.padic_math import padic_valuation
import pandas as pd

def load_gtex_codon_counts(tissue):
    """
    TODO: Implement GTEx data loading
    - Parse BAM files or gene-level counts
    - Extract codon frequencies per gene
    - Return: DataFrame with (gene, codon, count)
    """
    pass

def compute_codon_enrichment(motor_counts, other_counts, gene):
    """
    TODO: Implement codon enrichment calculation
    - For each codon in gene
    - Compute fold enrichment (motor / other)
    - Compute p-adic valuation
    - Test if v=0 codons are enriched
    """
    pass

def main():
    # ALS-associated genes
    als_genes = ['TARDBP', 'SOD1', 'FUS', 'C9ORF72']

    # TODO: Load data
    motor_counts = load_gtex_codon_counts('motor_cortex')
    other_counts = load_gtex_codon_counts('cerebellum')

    # TODO: Analyze each gene
    results = []
    for gene in als_genes:
        enrichment = compute_codon_enrichment(motor_counts, other_counts, gene)
        results.append(enrichment)

    # TODO: Statistical testing
    # TODO: Visualization
    # TODO: Save results

if __name__ == '__main__':
    main()
```

Similar templates for:
- `02_tdp43_ptm_sweep.py`
- `01_parkinsons_codon_bias.py`
- `01_ns1_ptm_sweep.py`

---

## 9. Success Criteria & Go/No-Go Decision Points

### 9.1 Phase 1 Go/No-Go (End of Week 4)

**Success Criteria:**
- [ ] Codon bias analysis shows v=0 enrichment > 1.5 for at least 2 ALS genes
- [ ] Parkinson's analysis shows similar pattern for SNCA or LRRK2
- [ ] Dengue NS1 PTM differences detected between serotypes

**Go Decision:** If ≥2 of 3 criteria met → Proceed to Phase 2
**No-Go Contingency:** If 0-1 met → Refocus on single disease with strongest signal

### 9.2 Phase 2 Go/No-Go (End of Week 8)

**Success Criteria:**
- [ ] Cross-disease PTM clustering shows silhouette score > 0.3
- [ ] At least one disease shows clear PTM-phenotype correlation
- [ ] Goldilocks validation applicable to ALS or Parkinson's

**Go Decision:** If ≥2 of 3 criteria met → Proceed to Phase 3
**No-Go Contingency:** Analyze diseases separately, skip cross-disease integration

### 9.3 Phase 3 Go/No-Go (End of Week 12)

**Success Criteria:**
- [ ] HLA-DR binding predictions show <500 nM for ≥3 epitopes per disease
- [ ] Cross-disease epitope analysis shows clustering by disease or allele
- [ ] Correlation with clinical data (DHF severity, ALS progression, etc.)

**Go Decision:** If ≥2 of 3 criteria met → Proceed to Phase 4
**No-Go Contingency:** Focus on Dengue DHF (strongest clinical application)

### 9.4 Final Publication Go/No-Go (End of Week 20)

**Minimum Publishable Unit:**
- At least ONE disease fully validated (all 5 phases complete)
- Cross-disease comparison (even if negative result is valuable)
- Novel PTM database contribution
- AlphaFold3 structural validation for key proteins

**High-Impact Publication:** Nature Communications, Cell Systems, PNAS
**Medium-Impact Publication:** PLoS Computational Biology, Bioinformatics, Nucleic Acids Research
**Domain Journal:** Journal of Neuroinflammation, Antiviral Research, Frontiers in Immunology

---

## 10. Long-Term Vision & Extensions

### 10.1 Beyond Phase 6 (Months 7-12)

**If validation succeeds:**

1. **Expand to other neurological diseases:**
   - Multiple Sclerosis (autoimmune demyelination)
   - Huntington's Disease (protein aggregation)
   - Prion diseases (misfolding propagation)

2. **Integrate with multi-omics:**
   - Proteomics: Validate PTM predictions experimentally
   - Metabolomics: Link codon bias to metabolic stress
   - Lipidomics: Parkinson's membrane interactions

3. **Clinical trial design:**
   - Dengue DHF: Prospective ADE risk assessment
   - ALS: Biomarker-guided clinical trials
   - Parkinson's: Precision medicine based on SNCA variants

### 10.2 Technology Development

**AI-Assisted Clinical Tools:**
- Real-time Dengue risk assessment app (input: patient serology + circulating serotypes)
- ALS progression predictor (input: patient RNA-seq)
- Parkinson's therapeutic response predictor (input: genetic variants)

**Database Contributions:**
- Unified PTM-disease database (public release)
- Cross-disease epitope atlas (HLA-DR binding across all diseases)
- Tissue-specific codon bias database (extend beyond GTEx)

### 10.3 Funding Opportunities

**Relevant Funding Agencies:**

- **NIH:** R01 for ALS/Parkinson's research
- **WHO/PAHO:** Dengue surveillance and prediction tools (Latin America focus)
- **NSF:** Computational biology methods development
- **Wellcome Trust:** Global health applications (Dengue)
- **Michael J. Fox Foundation:** Parkinson's biomarkers
- **ALS Association:** Therapeutic target identification

**Estimated Funding Potential:**
- NIH R01: $1.5-2M over 5 years
- WHO/PAHO: $500K-1M over 3 years
- Foundation grants: $250-500K over 2 years

---

## Conclusion

This comprehensive research plan leverages the mature p-adic codon embedding infrastructure to test a bold conjecture: **neurological and immune diseases share fundamental mechanisms visible in codon expression and PTM accumulation patterns**.

By integrating existing tools (TrainableCodonEncoder, PTM mapping, HLA binding, contact prediction, AlphaFold3 validation) with new disease-specific datasets (ALS, Parkinson's, Dengue DHF), we can:

1. **Validate tissue-specific codon bias** as a disease risk factor
2. **Unify PTM databases** across 5 major diseases
3. **Discover universal protein interaction failure mechanisms**
4. **Enable clinical translation** for Dengue risk assessment, ALS biomarkers, and Parkinson's precision medicine

The 24-week timeline with 6 phases provides clear milestones, go/no-go decision points, and contingency plans. Even partial success (validating a single disease) produces publishable results and extends the Alejandra Rojas arbovirus package.

**Immediate Action:** Proceed with Week 1 data acquisition and environment setup to begin Phase 1.

---

**Document Status:** Ready for implementation
**Next Review:** End of Week 4 (Phase 1 Go/No-Go decision)
**Contact:** AI Whisperers Research Team
